OBJECTIVE： To explore the safety and effects of liver function in patients with liver cirrhosis following virus B hepatitis （called “hepatitis B” for short） on drug half-life and analgesic effect of target controlled infusion of remifentanil. METHODS： 100 patients with liver cirrhosis following hepatitis B underwent liver and gallbladder surgery under selective general anesthesia were collected from our hospital and divided into group A （mild abnormal liver function） and group B （severe abnormal liver function， 3 cases withdrew from the test and 47 cases completed the test）， with 50 cases in each group， according to Child-Pugh grading of liver function. Both group were given phenobarbital sodium 0.1 g+scopolamine 0.3 mg intramuscularly 0.5 h before operation； midazolam 0.04 mg/kg+propofol 1.5 mg/kg+atracurium 0.6 mg/kg intravenously； target controlled infusion of Remifentanil hydrochloride for injection during operation with 0.125-0.250 μg/（kg·min）. The distribution half-life and the elimination half-life of remifentanil were determined，  and temperature pain perception threshold （tPDT） and electrical pain perception threshold （ePDT） were measured immediately after the operation； the occurrence of ADR was observed. RESULTS： The distribution and elimination half-life of remifentanil were （4.52±1.25）min and（24.64±1.30）min in group A and （4.68±1.31）min and（25.45±2.08）min in group B respectively， there was no statistical significance between 2 groups （P＞0.05）. tPDT and ePDT of group A were （8.88±1.66）mA and （1.54±0.09）mA respectively， and those of group B were （9.16±1.58）mA and （1.34±0.15） mA， there was no statistical significance between 2 groups （P＞0.05）. No obvious ADR was found in 2 groups. CONCLUSIONS： The abnormal liver function of patients with liver cirrhosis following hepatitis B have no significant effect on drug half-life and analgesic effect of remifentanil with good safety.